We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Dose-escalation study of oral etoposide and carboplatin in patients with advanced lung cancer.
- Authors
Atagi, S; Furuse, K; Kawahara, M; Kodama, N; Ogawara, M; Kubota, K; Matsui, K; Kusunoki, Y; Masuda, N; Takada, M; Negoro, S; Fukuoka, M
- Abstract
A dose-escalation study of daily etoposide and carboplatin was carried out on 23 patients with advanced lung cancer using a starting dose of 40 mg/m2/day etoposide given orally for 21 days and 250 mg/m2 carboplatin given intravenously (IV) on day 1. A total of 41 courses were given. Myelosuppression was the major dose-limiting toxicity. The maximum tolerated dose was reached at the fourth level with 40 mg/m2/day etoposide for 21 days and 400 mg/m2 carboplatin on day 1, once every 4 weeks. Non-hematological toxicities were generally mild or reversible. The recommended doses of this combination chemotherapy are 40 mg/m2/day etoposide for 21 days and 350 mg/m2 carboplatin on day 1. The response rate for non-small cell lung cancer and small cell lung cancer was 16.7% and 60% (95% confidence intervals of 3.6% to 41.4%, and 14.7% to 94.7%), respectively. A phase II study is necessary to define the efficacy and safety of this combination chemotherapy.
- Publication
Japanese journal of clinical oncology, 1996, Vol 26, Issue 5, p316
- ISSN
0368-2811
- Publication type
Journal Article
- DOI
10.1093/oxfordjournals.jjco.a023239